pubmed.ncbi.nlm.nih.gov

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters - PubMed

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters

Carel W le Roux et al. Ann Surg. 2006 Jan.

Abstract

Objective: To study the effect of bariatric surgery on the entero-hypothalamic endocrine axis of humans and rodents.

Background: Bariatric surgery is the most effective obesity treatment as it achieves substantial and sustained weight loss. Glycemic control and enhanced satiation improve before substantial weight loss occurs. Gut peptides, acting both peripherally and centrally, contribute to glycemic control and regulate food intake.

Methods: We examined meal-stimulated responses of insulin, ghrelin, peptide YY (PYY), glucagon-like-peptide-1 (GLP-1), and pancreatic polypeptide (PP) in humans and rodents following different bariatric surgical techniques.

Results: Compared with lean and obese controls, patients following Roux-en-Y gastric bypass (RYGB) had increased postprandial plasma PYY and GLP-1 favoring enhanced satiety. Furthermore, RYGB patients had early and exaggerated insulin responses, potentially mediating improved glycemic control. None of these effects were observed in patients losing equivalent weight through gastric banding. Leptin, ghrelin, and PP were similar in both the surgical groups. Using a rodent model of jejuno-intestinal bypass (JIB), we showed elevated PYY and GLP-1 in JIB rats compared with sham-operated rats. Moreover, exogenous PYY reduced food intake and blockade of endogenous PYY increased food intake. Thus, higher plasma PYY following JIB may contribute to reduced food intake and contribute to weight loss.

Conclusions: Following RYGB and JIB, a pleiotropic endocrine response may contribute to the improved glycemic control, appetite reduction, and long-term changes in body weight.

PubMed Disclaimer

Figures

None

FIGURE 1. A, The insulin response, C, GLP-1 responses and D, PYY response to test a meal in RYGB (▴), GB (▪), lean (⋄), and obese (O) subjects. B, The insulin increment between baseline and 15 minutes in the 4 groups.

None

FIGURE 2. A, The weight changes for the JIB (--■--) (n = 12), sham bypass (⦵) (n = 12), and sham bypass pair fed (⋯▲⋯) (n = 10) rats over 28 days. B, The average daily food intake of the JIB (--■--) and sham bypass (⦵) rats over 28 days. *P < 0.05.

None

FIGURE 3. Fasting plasma PYY and GLP-1 levels in the sham bypass (▪) (n = 6) and JIB (□) rats (n = 6). *P < 0.05.

Comment in

Similar articles

Cited by

References

    1. Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–643. - PubMed
    1. Kortt MA, Langley PC, Cox ER. A review of cost-of-illness studies on obesity. Clin Ther. 1998;20:772–779. - PubMed
    1. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature. 2000;404:672–677. - PubMed
    1. Vage V, Solhaug JH, Berstad A, et al. Jejunoileal bypass in the treatment of morbid obesity: a 25-year follow-up study of 36 patients. Obes Surg. 2002;12:312–318. - PubMed
    1. Mitchell JE, Lancaster KL, Burgard MA, et al. Long-term follow-up of patients’ status after gastric bypass. Obes Surg. 2001;11:464–468. - PubMed

Publication types

MeSH terms

Substances